* The COMET study was divided into 2 parts. The Year 2 population must have finished Year 1 and had at least 1 visit in Year 2.1
† The numbers of patients for the CRP analysis were ENBREL + MTX=107 and MTX=91.1
The numbers of patients for the CRP analysis were ENBREL + MTX=107 and MTX=91.1
The ITT population (N=411) was defined as all subjects who received at least 1 dose of study drug during Period 2
In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.
In moderate to severe RA
Evaluated in RA clinical studies over the past 20 years*
To return to ENBREL.com, click "Cancel" or close this window.
Your e-mail was sent successfully.
Send another e-mail
Return to enbrel.com/RheumPro
This content is not available at this time.
The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.
If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.